Detalhe da pesquisa
1.
Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
J Infect Dis
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437622
2.
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
Blood
; 139(7): 1026-1038, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496014
3.
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Blood
; 139(3): 413-423, 2022 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570876
4.
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
Am J Hematol
; 98(2): 300-308, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588409
5.
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.
J Natl Compr Canc Netw
; 20(5): 436-442, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545171
6.
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Br J Haematol
; 195(2): 201-209, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34341990
7.
Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.
Cancer Immunol Immunother
; 70(3): 869-874, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32857184
8.
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Haematologica
; 106(6): 1705-1713, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32414850
9.
Effect of malnutrition-driven nutritional support protocol on clinical outcomes in autologous stem cell transplantation patients.
Support Care Cancer
; 29(2): 997-1003, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32556621
10.
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Cancer
; 126(2): 293-303, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31568564
11.
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy.
Br J Haematol
; 189(2): 313-317, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31804715
12.
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
N Engl J Med
; 377(26): 2545-2554, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29226764
13.
Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.
Blood
; 132(10): 1022-1026, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29925499
14.
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.
J Natl Compr Canc Netw
; 18(1): 12-22, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31910384
15.
Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma.
Am J Hematol
; 95(3): 238-244, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31804739
16.
Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients.
Biol Blood Marrow Transplant
; 25(5): 1004-1010, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30481595
17.
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Oncologist
; 24(7): 955-962, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30568021
18.
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Blood
; 128(18): 2199-2205, 2016 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27601462
19.
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
Haematologica
; 103(5): 874-879, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29419429
20.
Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.
Cytotherapy
; 20(12): 1415-1418, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30385043